Literature DB >> 29269208

Bright Light as a Preventive Intervention for Depression in Late-Life: A Pilot Study on Feasibility, Acceptability, and Symptom Improvement.

Amanda N Leggett1, Deirdre A Conroy2, Frederic C Blow3, Helen C Kales4.   

Abstract

OBJECTIVES: We examined the feasibility and acceptability of a portable bright light intervention and its impact on sleep disturbance and depressive symptoms in older adults.
METHODS: One-arm prevention intervention pilot study of the Re-Timer (Re-Timer Pty Ltd, Adelaide, Australia) bright light device (worn 30 minutes daily for 2 weeks) in 1 older adults (age 65 + years) with subsyndromal symptoms of depression and poor sleep quality. Participants were assessed on intervention acceptability and adherence, depressive symptoms (Patient Health Questionnaire- 9), and sleep (Pittsburgh Sleep Quality Index, Insomnia Severity Index, actigraphy and daily diary reports).
RESULTS: The Re-Timer device was rated positively by participants, and, on average, participants only missed 1 day of utilization. Although depressive symptoms declined and self-reported sleep improved, improvement was seen largely before the start of intervention.
CONCLUSIONS: An effective preventive intervention that is targeted towards a high risk group of older adults has the potential to reduce distress and costly health service use.
Copyright © 2017 American Association for Geriatric Psychiatry. All rights reserved.

Entities:  

Keywords:  Sleep disturbance; depressive symptoms; intervention; light therapy; prevention

Mesh:

Year:  2017        PMID: 29269208      PMCID: PMC6181116          DOI: 10.1016/j.jagp.2017.11.007

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  9 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

2.  A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms.

Authors:  J A Horne; O Ostberg
Journal:  Int J Chronobiol       Date:  1976

3.  Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.

Authors:  Ritsaert Lieverse; Eus J W Van Someren; Marjan M A Nielen; Bernard M J Uitdehaag; Jan H Smit; Witte J G Hoogendijk
Journal:  Arch Gen Psychiatry       Date:  2011-01

Review 4.  Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies.

Authors:  Chiara Baglioni; Gemma Battagliese; Bernd Feige; Kai Spiegelhalder; Christoph Nissen; Ulrich Voderholzer; Caterina Lombardo; Dieter Riemann
Journal:  J Affect Disord       Date:  2011-02-05       Impact factor: 4.839

Review 5.  Adherence to depression treatment in older adults: a narrative review.

Authors:  Kara Zivin; Helen C Kales
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 6.  Bright light therapy for sleep problems in adults aged 60+.

Authors:  P Montgomery; J Dennis
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Light therapy for insomnia in older adults.

Authors:  Julie K Gammack
Journal:  Clin Geriatr Med       Date:  2008-02       Impact factor: 3.076

8.  Low illumination experienced by San Diego adults: association with atypical depressive symptoms.

Authors:  R C Espiritu; D F Kripke; S Ancoli-Israel; M A Mowen; W J Mason; R L Fell; M R Klauber; O J Kaplan
Journal:  Biol Psychiatry       Date:  1994-03-15       Impact factor: 13.382

9.  The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.

Authors:  D J Buysse; C F Reynolds; T H Monk; S R Berman; D J Kupfer
Journal:  Psychiatry Res       Date:  1989-05       Impact factor: 3.222

  9 in total
  1 in total

1.  Efficacy of light therapy on nonseasonal depression among elderly adults: a systematic review and meta-analysis.

Authors:  Chun-Hung Chang; Chieh-Yu Liu; Shaw-Ji Chen; Hsin-Chi Tsai
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-14       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.